Small molecules & peptides

DOTA-TOC (GMP)

Precursor for radiolabelled DOTA-TOC

DOTA-TOC acetate; DOTA-[Tyr3]-octreotide; Edotreotide; CA index name: L-Cysteinamide, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic(2→7)-disulfide, supplied as acetate salt

Sequence: DOTA-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol), cyclic disulfide

Quality

GMP Product

Characteristics

Molar mass 1421.7 (net peptide)

CAS RN [204318-14-9]

Purity ≥ 98 %

  • White to off-white powder

Certificates

CoA: appearance, HPLC (identity, purity, assay), GC (residual Solvents, water content, counter-ion), microbiology test

Product sheets (PDF)

Literature

Forrer F. et al. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006, 26, 703–707.

Koukouraki S. et al. Evaluation of the pharmacokinetics of (68)Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 460–466.

Add to inquiry

Product No.Filling amountQuantity
Product No.: 9702

Related products

Product was added